Maravai LifeSciences (MRVI) Projected to Post Earnings on Tuesday

Maravai LifeSciences (NASDAQ:MRVI) is expected to issue its quarterly earnings data after the market closes on Tuesday, February 25th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $57.79 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Maravai LifeSciences Trading Up 4.1 %

NASDAQ:MRVI opened at $4.11 on Monday. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The stock has a market capitalization of $1.04 billion, a PE ratio of -2.51 and a beta of -0.08. The firm’s 50 day moving average is $5.06 and its 200 day moving average is $6.64. Maravai LifeSciences has a 12 month low of $3.93 and a 12 month high of $11.56.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on MRVI shares. William Blair reaffirmed a “market perform” rating on shares of Maravai LifeSciences in a report on Friday, November 8th. Royal Bank of Canada lowered their price target on shares of Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. Wolfe Research started coverage on shares of Maravai LifeSciences in a report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Robert W. Baird lowered their price target on shares of Maravai LifeSciences from $10.00 to $9.00 and set an “outperform” rating on the stock in a report on Friday, November 8th. Finally, The Goldman Sachs Group cut shares of Maravai LifeSciences from a “neutral” rating to a “sell” rating and lowered their price target for the stock from $7.00 to $4.25 in a report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Maravai LifeSciences currently has a consensus rating of “Hold” and a consensus target price of $10.32.

Insider Buying and Selling at Maravai LifeSciences

In other news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $5.03, for a total transaction of $125,750.00. Following the completion of the transaction, the general counsel now directly owns 167,618 shares in the company, valued at $843,118.54. The trade was a 12.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.63% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.